Relay Therapeutics, Inc. Common Stock (RLAY) is a publicly traded Healthcare sector company. As of July 16, 2026, RLAY trades at $19.41 with a market cap of $4.16B and a P/E ratio of -12.60. RLAY moved +0.05% today. Year to date, RLAY is +130.62%; over the trailing twelve months it is +457.43%. Its 52-week range spans $1.78 to $20.79. Analyst consensus is strong buy with an average price target of $24.00. Rallies surfaces RLAY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for RLAY, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $19.41 |
| Market Cap | $4.16B |
| P/E Ratio | -12.60 |
| EPS | $-1.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.79 |
| 52-Week Low | $1.78 |
| Volume | 1.11M |
| Avg Volume | 0 |
| Revenue (TTM) | $10.68M |
| Net Income | $-272.70M |
| Gross Margin | 0.00% |
11 analysts cover RLAY: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.00.